PCSK9 and metabolic syndrome: Those with mixed dyslipidemia may benefit from polytherapy from the addition of drugs such as ezetimibe, bile acid sequestrants, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, or adenosine triphosphate-citrate lyase inhibitors.